RP 3128Alternative Names: RP3128
Latest Information Update: 14 Nov 2016
At a glance
- Originator Rhizen Pharmaceuticals
- Class Antiasthmatics; Small molecules
- Mechanism of Action ORAI1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Asthma
Most Recent Events
- 01 Oct 2016 Phase-I/II clinical trials in Asthma in Canada (PO) (NCT02958982)